Montelukast Sodium Market Trends, Demand, Growth and Key players 2027
The Global Montelukast
Sodium Market is estimated to be valued at USD 1,430,215.2 thousand and is
expected to register a CAGR of 3.38% during the forecast period.
The asthma segment is expected to lead the market and
register a substantial CAGR to reach USD 700,730.7 thousand by the end of
forecast owing to the rising prevalence of asthma. Montelukast API is much in
demand across the globe for the treatment of asthma. However, the allergic
rhinitis segment is projected to exhibit the highest CAGR of 3.11%. The rising
rate of allergic rhinitis cases is driving the growth of the segment.
North America accounted for the largest market share of
39.25% in 2017, and the regional market is projected to register a CAGR of
3.12% during the forecast period. Asia-Pacific is expected to register the
fastest CAGR. The Chinese market is projected to exhibit the highest growth
rate of 5.10% during the forecast period.
Segment Analysis
The global montelukast API market has been segmented on the
basis of applications, and region. On the basis of the applications, the market
has been divided into asthma, allergic rhinitis, bronchospasm, urticarial and
others. The asthma segment held the majority market share in 2017. Allergic
rhinitis segment is expected to be the fastest-growing, followed by the asthma
segment. Rising prevalence of allergic rhinitis is driving the growth of the
segment.
Market Players
Market Research Future (MRFR) recognizes Merck Sharp &
Dohme Corp (US), Dr. Reddy’s Laboratories Ltd (India), Morepen Laboratories Ltd
(India), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (Israel), Hikma
Pharmaceuticals PLC (UK), Glenmark (India), Sandoz International GmbH
(Germany), Vintage Pharmaceuticals Inc (US), Hetero (India) and Aurobindo
Pharma (India) as the key players in the global montelukast API market.
Regional Analysis
North America accounted for the largest market share of
39.25% in 2017, and the regional market is projected to register a CAGR of
3.12% during the forecast period. Asia-Pacific is expected to register the
fastest CAGR. The Chinese market is projected to exhibit the highest growth
rate of 5.10% during the forecast period from 2018 to 2023.
The European market is estimated to exceed USD 396,258
thousand by 2023. Increasing incidence of asthma, COPD, and allergies are
driving the growth of the Montelukast API market in the region. The UK is the
major contributor to the growth of the regional market, followed by France.
Key Findings of the Study:
The Global Montelukast API Market is projected to reach over
USD 1,430,215.2 thousand by 2023 at 38% CAGR during the review period of 2018
to 2023.
North America accounted for the largest market share with
the US being the major contributor to the growth of the market.
The allergic rhinitis segment is projected to register the
highest CAGR of 3.89% during the forecast period owing to the rising rate of
allergic rhinitis cases.
Key manufacturers are adopting geographic expansions,
corporate acquisitions, and product launches as growth strategies.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Comments
Post a Comment